Pharmaceuticals Singapore

Singapore Pet Pharmaceuticals Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Singapore Pet Pharmaceuticals Market Industry Trends and Forecast to 2034: Segmented by (Product, Animal, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Singapore · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $28.8 Mn Placeholder estimate
Estimate 2025 $31.1 Mn 0.1% of the global market
Projected 2034 $61.6 Mn 98.2% Adds $30.5 Mn over 9 forecast years
CAGR 2025–2034 7.9% Faster than 42% of 180 Pharmaceuticals markets here
Key players 5
  • Singapore is 0.14% of the global market.
  • In APAC, the largest is China at $2.09 Bn.
  • Fastest growing: India at 9.9% a year.
  • Singapore ranks 9th of 10 by size in APAC.

Market size projection

Singapore

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$30.5 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Pet Pharmaceuticals Market market size by year, Singapore
YearMarket sizeChange that yearSince 2025
2024 (estimate) $28.8 Mn — —
2025 (base) $31.1 Mn +$2.3 Mn —
2026 (forecast) $33.5 Mn +$2.5 Mn +7.9%
2027 (forecast) $36.2 Mn +$2.6 Mn +16.4%
2028 (forecast) $39.0 Mn +$2.9 Mn +25.6%
2029 (forecast) $42.1 Mn +$3.1 Mn +35.5%
2030 (forecast) $45.5 Mn +$3.3 Mn +46.3%
2031 (forecast) $49.1 Mn +$3.6 Mn +57.8%
2032 (forecast) $52.9 Mn +$3.9 Mn +70.3%
2033 (forecast) $57.1 Mn +$4.2 Mn +83.7%
2034 (forecast) $61.6 Mn +$4.5 Mn +98.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Singapore Pet Pharmaceuticals Market Analysis at a glance
Market size, 2025$31.1 Mn placeholder estimate
Forecast, 2034$61.6 Mn placeholder estimate
Growth (CAGR), 2025–20347.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct and animal (see all)
Key playersZoetis, Inc, Elanco, Boehringer Ingelheim GmbH, Merck & Co., Inc., Virbac (see all)
Regulator in SingaporeHSASource: Health Sciences Authority. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Singapore Pet Pharmaceuticals Market Analysis Executive Summary

Pet pharmaceuticals treat dogs, cats and other pets for parasites, pain, allergies, infections and chronic diseases.

Key segments of the pet Pharmaceuticals market include product (Parasiticides, Anti-Inflammatories and Antibiotics) and animal (Dogs, Cats and Others).

Bar chart: Singapore Pet Pharmaceuticals market size, 2024–2034, placeholder estimates. $28.8 Mn in 2024, $31.1 Mn in 2025 and $61.6 Mn in 2034, 7.9% CAGR.
Singapore Pet Pharmaceuticals market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Singapore Pet Pharmaceuticals Market Dynamics

Market Growth Drivers

More pets per household, owners treating pets as family, livestock disease risks and the One Health approach linking animal and human health are driving the pet Pharmaceuticals market.

Opportunity

Pet insurance, diagnostics and vaccines for emerging animal diseases give the pet Pharmaceuticals market room to grow.

Market Restraints

Cost-sensitive farmers, fewer vets in rural areas, rules on antibiotic use in animals and slow approvals hold back the pet Pharmaceuticals market.

Competitive Landscape for Pet Pharmaceuticals Market in Singapore

The pet Pharmaceuticals market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Pet Pharmaceuticals Market in Singapore

Pet Pharmaceuticals in Singapore: rules and payment

Therapeutic products need registration with the Health Sciences Authority (HSA).⁠[1] MediShield Life gives basic health insurance to all citizens and permanent residents, alongside MediSave savings accounts.⁠[2]

[1] Health Sciences Authority. Checked 14 Nov 2026.

[2] CPF Board, MediShield Life. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for pet Pharmaceuticals. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Singapore.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Pet Pharmaceuticals right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Pet Pharmaceuticals in context

Singapore compared

  • Health spending per person: 3,922 US$ per person (2023). World: 1,317 US$ per person (2023). 3rd highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.83 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 4th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 14.2% of people (2025). World: 10.4% of people (2025). 7th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Pet Pharmaceuticals market in Singapore?
Placeholder estimate: about $31.1 Mn in 2025, rising to about $61.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Pet Pharmaceuticals market in Singapore growing?
Placeholder estimate: about 7.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Pet Pharmaceuticals market report cover?
The report splits the market by product (Parasiticides, Anti-Inflammatories, Antibiotics, Dermatology Drugs) and animal (Dogs, Cats, Others).
Who are the key players in the Pet Pharmaceuticals market?
Key players include Zoetis, Inc, Elanco, Boehringer Ingelheim GmbH, Merck & Co., Inc. and Virbac.
What is driving the Pet Pharmaceuticals market?
More pets per household, owners treating pets as family, livestock disease risks and the One Health approach linking animal and human health are driving the pet Pharmaceuticals market.
Who regulates Pet Pharmaceuticals in Singapore?
Therapeutic products need registration with the Health Sciences Authority (HSA). Source: Health Sciences Authority. Checked 14 Nov 2026.
How is healthcare paid for in Singapore?
MediShield Life gives basic health insurance to all citizens and permanent residents, alongside MediSave savings accounts. Source: CPF Board, MediShield Life. Checked 14 Nov 2026.
How much research is published on Pet Pharmaceuticals?
PubMed lists 6 papers on Pet Pharmaceuticals added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Singapore

See all

Related on animal health

See the topic